In addition, it has been recently demonstrated, in BC cell lines including TNBC cells, that treatment with CDK4/6 inhibitors triggers anti-tumor immunity by enhancing tumor antigen presentation and suppressing regulatory T cells proliferation [28], thus opening new perspectives in the use of CDK4/6 inhibitors in association with immunotherapies. This evidence concerns the gene CDK4 and neoplasm.